News - Pharmaceuticals
Pharmacy Guild pushes medicines affordability campaign as consumers delay filling scripts

Pharma News: Medicines are unaffordable to many Australians as the rising cost of living collides with the rising cost of prescription medicines, according to a new Pharmacy Guild consumer campaign.
Medicines on the Pharmaceutical Benefits Scheme (PBS) cost non-concessional patients $42.50 per prescription after the maximum co-payment went up on 1 January 2022. The co-payment for general patients has doubled since 2000 and according to the latest ABS figures, more than 900,000 Australians delayed or didn’t fill scripts in 2019-20 due to cost.
In a recently commissioned research by the Pharmacy Guild, targeting 15 marginal Federal electorates^, affordability of healthcare was the number one concern for voters. Thirteen per cent (13%) said they have gone without prescribed medicines because they could not afford them.
Interestingly, in the Australian Healthcare Index report* of 4,000 consumers, while 19% did not find prescriptions affordable, only 5% agreed with the statement that “I can’t afford to get the prescriptions I need”.
The National President of the Pharmacy Guild of Australia, Professor Trent Twomey, said that patients were increasingly asking pharmacists which of the medicines prescribed by their GP could be skipped to save money.
“This is a dangerous trend, as prescribed medications are designed to work together to preserve the health and ultimately save the lives of the patients who need them,” Professor Twomey said.
UTS modelling has found that hospitalisations and loss of productivity due to a failure to take medicines as instructed by medical professionals could cost the federal budget $10.4 billion in a year for hypertension, dyslipidemia and depression conditions alone.
He added “Pharmacists are worried that there will be more preventable ill-health and even deaths as people are increasingly finding themselves having to choose between buying the medicines they need and other essential items like rent, groceries and petrol.”
Medicines Australia CEO, Elizabeth de Somer, told Health Industry Hub “All Australians deserve fast, equitable access to medicines, no matter their circumstances. Medicines Australia works closely with the Government, and other stakeholders to ensure the best possible outcomes for patients, including highlighting the need for reform on cost and timely access when and where it is needed.
“Medicines Australia’s Strategic Agreement and the upcoming independent HTA review will have an impact on affordability and time to access medicines. The review of the National Medicines Policy (NMP) is also an important piece that will affect all Australians. A new and appropriate NMP can play an important part in improving equitable access to medicines, as long as all Australians and its diverse communities are adequately reflected and consulted.”
*Produced by Healthengine and the Australian Patients Association in October 2021
^Flynn, Bowman, Dobell, Robertson, Reid, Gilmore, Lindsay, Macquarie, Kooyong, Bass, Braddon, Corangamite, Broothby, Cowan, Swan
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More